Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

We recently compiled a list of the 10 High Growth Restaurant Stocks For 2025. In this article, we are going to take a look at ...

The success of the Public Offer and the broad participation of the investing public is both a vindication of, and a vote of ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The U.S. IPO market is moving forward with a steady flow of applicants. Investors this week are awaiting the U.S. Fed's ...

Investors typically celebrate IPOs as milestone moments — and potential exit opportunities — for their startups. In an ...

Snag is, Cheniere’s two export terminals are already advanced enough to generate several billion dollars in cash flow, much of which is already flowing in dividends to shareholders. Venture Global is ...

Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO ...

The 1975 Emergency underscored the need to safeguard rights and uphold democratic checks and balances Erosion of freedoms and ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Czech steam-turbine manufacturer Doosan Skoda Power AS launched an initial public offering, touting an outlook for high ...

Weight-loss drug developer Metsera on Monday said it was is targeting to raise as much as $292.2 million in an initial public offering.